Research Paper Volume 13, Issue 12 pp 16341—16352

Figure 3. Ropivacaine enhances the expression of miR-27b-3p in breast cancer cells. (A) The expression of miR-27b-3p was detected in the tumor and peri-tumor tissues from breast cancer patients (n = 50). (B) The expression of miR-27b-3p was analyzed in the indicated cells. (C) The MCF-7 and MDA-MB-231 cells were treated with ropivacaine (1 mmol/L) or equal volume saline. The expression of miR-27b-3p was measured by qPCR assays in the cells. (D–H) The MCF-7 and MDA-MB-231 cells were treated with control mimic or miR-27b-3p mimic (50 nM) for 48 hours. (D) The cell viability was analyzed by the MTT assays in the cells. (E and F) The cell apoptosis was measure by flow cytometry analysis in the cells. (G and H) The cell migration and invasion were examined by transwell assays in the cells. N = 3, The independent experiments were repeated for three times. Data are presented as mean ± SD. Statistic significant differences were indicated: ^*P < 0.05, ^**P < 0.01.